PE20141189A1 - Preparacion de liberacion sostenida - Google Patents
Preparacion de liberacion sostenidaInfo
- Publication number
- PE20141189A1 PE20141189A1 PE2014000558A PE2014000558A PE20141189A1 PE 20141189 A1 PE20141189 A1 PE 20141189A1 PE 2014000558 A PE2014000558 A PE 2014000558A PE 2014000558 A PE2014000558 A PE 2014000558A PE 20141189 A1 PE20141189 A1 PE 20141189A1
- Authority
- PE
- Peru
- Prior art keywords
- sustained release
- release preparation
- pioglitazone
- gel
- water
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A UNA PREPARACION DE LIBERACION SOSTENIDA QUE COMPRENDE: A) PIOGLITAZONA EN UNA CANTIDAD DE 0,1 A 8MG O UNA SAL DE PIOGLITAZONA TAL COMO CLORHIDRATO; B) UN POLIMERO FORMADOR DE GEL TAL COMO OXIDO DE POLIETILENO QUE TIENE UN PESO MOLECULAR DE 1.000.000 A 4.000.000 Y SE ENCUENTRA EN UNA CANTIDAD DE 50 A 80% EN PESO DE LA PREPARACION; Y C) UN PROMOTOR FORMADOR DE GEL TAL COMO i) UNA BASE HIDROFILICA SOLUBLE EN AGUA TAL COMO LACTOSA, GLUCOSA, MANITOL O TREHALOSA, O ii) UNA BASE HIDROFILICA INSOLUBLE EN AGUA TAL COMO ALMIDON PARCIALMENTE PREGELATINIZADO, CROSPOVIDONA, CELULOSA CRISTALINA, ENTRE OTROS. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011232302 | 2011-10-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20141189A1 true PE20141189A1 (es) | 2014-09-24 |
Family
ID=47178262
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2014000558A PE20141189A1 (es) | 2011-10-21 | 2012-10-19 | Preparacion de liberacion sostenida |
Country Status (29)
Country | Link |
---|---|
US (1) | US9907789B2 (es) |
EP (1) | EP2768487B1 (es) |
JP (1) | JP6093762B2 (es) |
KR (1) | KR20140081826A (es) |
CN (1) | CN104039313A (es) |
AP (1) | AP2014007645A0 (es) |
AR (1) | AR088398A1 (es) |
AU (1) | AU2012326976B2 (es) |
BR (1) | BR112014008744A2 (es) |
CA (1) | CA2852417A1 (es) |
CL (1) | CL2014000992A1 (es) |
CO (1) | CO6960544A2 (es) |
CR (1) | CR20140213A (es) |
DO (1) | DOP2014000077A (es) |
EA (1) | EA201490840A1 (es) |
EC (1) | ECSP14013328A (es) |
IL (1) | IL232114A0 (es) |
IN (1) | IN2014DN03169A (es) |
MA (1) | MA35717B1 (es) |
MX (1) | MX2014004679A (es) |
NZ (1) | NZ624275A (es) |
PE (1) | PE20141189A1 (es) |
SG (2) | SG10201700121YA (es) |
TN (1) | TN2014000152A1 (es) |
TW (1) | TW201323018A (es) |
UA (1) | UA113858C2 (es) |
UY (1) | UY34403A (es) |
WO (1) | WO2013058409A1 (es) |
ZA (1) | ZA201403103B (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2852417A1 (en) | 2011-10-21 | 2013-04-25 | Takeda Pharmaceutical Company Limited | Sustained-release preparation |
PE20141558A1 (es) | 2012-04-20 | 2014-11-06 | Gilead Sciences Inc | Derivados de acido benzotiazol-6-il acetico y su uso para tratar una infeccion por vih |
US20150141517A1 (en) * | 2013-11-15 | 2015-05-21 | Shin-Etsu Chemical Co., Ltd. | Granulated composite, rapid release tablet and method for producing same |
KR102485766B1 (ko) | 2019-12-11 | 2023-01-09 | 한국유나이티드제약 주식회사 | 생체이용률이 향상된 피오글리타존 함유 약학조성물 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4810502A (en) | 1987-02-27 | 1989-03-07 | Alza Corporation | Pseudoephedrine brompheniramine therapy |
US4820522A (en) | 1987-07-27 | 1989-04-11 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
JPH0624991A (ja) | 1991-06-20 | 1994-02-01 | Tokyo Tanabe Co Ltd | ウルソデスオキシコール酸持続性製剤 |
JPH0624959A (ja) | 1991-10-04 | 1994-02-01 | Bayer Yakuhin Kk | 胃内浮遊型薬物徐放性固形製剤 |
DK0661045T3 (da) | 1992-09-18 | 2002-10-28 | Yamanouchi Pharma Co Ltd | Hydrogelpræparat med forsinket frigivelse |
JPH06316517A (ja) | 1993-02-22 | 1994-11-15 | Grelan Pharmaceut Co Ltd | 放出制御製剤 |
AU8532798A (en) | 1997-06-13 | 1998-12-30 | Roland Bodmeier | Compounds which delay the release of active substances |
US6191154B1 (en) * | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
EP1413315A4 (en) | 2001-08-03 | 2006-08-16 | Takeda Pharmaceutical | DRUGS WITH CONTINUOUS RELEASE |
KR101363679B1 (ko) | 2002-09-20 | 2014-02-14 | 안드렉스 랩스 엘엘씨 | 약제학적 정제 |
US9060941B2 (en) | 2002-09-20 | 2015-06-23 | Actavis, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
JP4493970B2 (ja) | 2002-10-16 | 2010-06-30 | 武田薬品工業株式会社 | 持続性製剤 |
MY148805A (en) | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
IN192749B (es) | 2002-11-15 | 2004-05-15 | Ranbaxy Lab Ltd | |
US7442387B2 (en) | 2003-03-06 | 2008-10-28 | Astellas Pharma Inc. | Pharmaceutical composition for controlled release of active substances and manufacturing method thereof |
EP1607088B1 (en) | 2003-03-17 | 2019-02-27 | Takeda Pharmaceutical Company Limited | Controlled release composition |
JP4933033B2 (ja) | 2003-03-17 | 2012-05-16 | 武田薬品工業株式会社 | 放出制御組成物 |
CN1802178A (zh) | 2003-06-06 | 2006-07-12 | 武田药品工业株式会社 | 固体制剂 |
JP2005015477A (ja) | 2003-06-06 | 2005-01-20 | Takeda Chem Ind Ltd | 固形製剤 |
US20060003002A1 (en) | 2003-11-03 | 2006-01-05 | Lipocine, Inc. | Pharmaceutical compositions with synchronized solubilizer release |
US8263121B2 (en) | 2004-04-14 | 2012-09-11 | Takeda Pharmaceutical Company Limited | Solid pharmaceutical preparation |
MX2007002375A (es) | 2004-08-31 | 2007-04-23 | Pfizer Prod Inc | Formas de dosificacion de liberacion controlada combinando liberacion inmediata y liberacion sostenida de un farmaco de baja solubilidad. |
US20080262047A1 (en) | 2005-09-22 | 2008-10-23 | Allen D Roses | Ppar-Gamma Agonists for Improvement of Cognitive Function in Apoe4 Negative Patients |
WO2007054976A2 (en) | 2005-11-08 | 2007-05-18 | Panacea Biotec Ltd. | Lipid based controlled release pharmaceutical composition |
UA91729C2 (ru) | 2005-12-22 | 2010-08-25 | Такеда Фармасьютикал Компани Лимитед | Твердая форма лекарственного препарата |
TWI449542B (zh) | 2006-03-30 | 2014-08-21 | Nippon Zoki Pharmaceutical Co | 固形醫藥製劑 |
TW200800299A (en) | 2006-04-27 | 2008-01-01 | Takeda Pharmaceutical | Pharmaceutical composition |
CN101674811B (zh) | 2007-02-09 | 2015-08-19 | 阿尔法制药有限公司 | 含有两种或更多种不同物理形态的活性药物成分的剂型 |
TW200914006A (en) * | 2007-07-12 | 2009-04-01 | Takeda Pharmaceutical | Coated preparation |
CN101269040A (zh) * | 2008-05-16 | 2008-09-24 | 北京正大绿洲医药科技有限公司 | 盐酸吡格列酮缓释滴丸及其制备方法 |
WO2010039690A1 (en) | 2008-09-30 | 2010-04-08 | The Trustees Of The University Of Pennsylvania | Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors |
TWI478712B (zh) * | 2008-09-30 | 2015-04-01 | Astellas Pharma Inc | 釋控性醫藥組成物 |
JP5827952B2 (ja) | 2009-10-09 | 2015-12-02 | ユンジン・ファーム・カンパニー・リミテッドYungjin Pharm. Co. Ltd. | 速効性と持続性を同時に有する薬剤学的組成物 |
JP2011232302A (ja) | 2010-04-30 | 2011-11-17 | Ricoh Elemex Corp | 画像検査方法及び画像検査装置 |
CN101884627B (zh) * | 2010-07-07 | 2012-01-25 | 青岛黄海制药有限责任公司 | 盐酸吡格列酮胃内滞留缓释片及其制备方法 |
EP2665479B1 (en) * | 2011-01-10 | 2019-06-26 | Zinfandel Pharmaceuticals, Inc. | Methods and drug products for treating alzheimer's disease |
CA2852417A1 (en) | 2011-10-21 | 2013-04-25 | Takeda Pharmaceutical Company Limited | Sustained-release preparation |
KR20160056691A (ko) | 2014-11-12 | 2016-05-20 | 삼성에스디아이 주식회사 | 이차전지 |
-
2012
- 2012-10-19 CA CA2852417A patent/CA2852417A1/en not_active Abandoned
- 2012-10-19 UA UAA201405332A patent/UA113858C2/uk unknown
- 2012-10-19 TW TW101138592A patent/TW201323018A/zh unknown
- 2012-10-19 NZ NZ624275A patent/NZ624275A/en not_active IP Right Cessation
- 2012-10-19 WO PCT/JP2012/077662 patent/WO2013058409A1/en active Application Filing
- 2012-10-19 UY UY0001034403A patent/UY34403A/es not_active Application Discontinuation
- 2012-10-19 AP AP2014007645A patent/AP2014007645A0/xx unknown
- 2012-10-19 MX MX2014004679A patent/MX2014004679A/es unknown
- 2012-10-19 US US14/352,785 patent/US9907789B2/en active Active
- 2012-10-19 EA EA201490840A patent/EA201490840A1/ru unknown
- 2012-10-19 BR BR112014008744A patent/BR112014008744A2/pt not_active IP Right Cessation
- 2012-10-19 AU AU2012326976A patent/AU2012326976B2/en not_active Ceased
- 2012-10-19 AR ARP120103908A patent/AR088398A1/es unknown
- 2012-10-19 JP JP2014518853A patent/JP6093762B2/ja not_active Expired - Fee Related
- 2012-10-19 SG SG10201700121YA patent/SG10201700121YA/en unknown
- 2012-10-19 SG SG2014012025A patent/SG2014012025A/en unknown
- 2012-10-19 CN CN201280062591.4A patent/CN104039313A/zh active Pending
- 2012-10-19 PE PE2014000558A patent/PE20141189A1/es not_active Application Discontinuation
- 2012-10-19 EP EP12784752.3A patent/EP2768487B1/en active Active
- 2012-10-19 KR KR1020147010504A patent/KR20140081826A/ko not_active Application Discontinuation
- 2012-10-19 IN IN3169DEN2014 patent/IN2014DN03169A/en unknown
-
2014
- 2014-04-11 TN TNP2014000152A patent/TN2014000152A1/en unknown
- 2014-04-13 IL IL232114A patent/IL232114A0/en unknown
- 2014-04-15 DO DO2014000077A patent/DOP2014000077A/es unknown
- 2014-04-17 CL CL2014000992A patent/CL2014000992A1/es unknown
- 2014-04-29 ZA ZA2014/03103A patent/ZA201403103B/en unknown
- 2014-04-29 EC ECSP14013328 patent/ECSP14013328A/es unknown
- 2014-05-09 CR CR20140213A patent/CR20140213A/es unknown
- 2014-05-14 CO CO14103846A patent/CO6960544A2/es unknown
- 2014-05-15 MA MA37034A patent/MA35717B1/fr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019500517A1 (en) | Long-acting formulations of insulins | |
AR081681A1 (es) | METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA | |
AR084285A1 (es) | Composiciones inmunogenicas | |
EA201490538A1 (ru) | Лечение кашля и его приступов | |
PE20141189A1 (es) | Preparacion de liberacion sostenida | |
GT201500035A (es) | Composición farmacéutica oral en forma de microesferas y proceso de elaboración | |
CO7151496A2 (es) | Agentes terapeúticos para administración subcutánea optimizados | |
CY1118036T1 (el) | Βελτιστοποιημενη συνθεση καθαρων μη-πολυμορφικων, κρυσταλλικων χολικων οξεων με καθορισμενο μεγεθος σωματιδιων | |
EA201390979A1 (ru) | Композиции бензимидазолов с модифицированным высвобождением | |
MX349364B (es) | Variante de alfa-1 antitripsina novedosa, método de preparación de la misma, y uso de la misma. | |
TR200806300A2 (tr) | Çözünürlük artırıcı farmasötlk formulasyon | |
PE20140962A1 (es) | Una formulacion farmaceutica solida | |
BR112014016804A2 (pt) | composições, métodos de uso e métodos de tratamento | |
IN2014DN10134A (es) | ||
ES2552521T3 (es) | Infusión intravenosa de ibuprofeno | |
AR082806A1 (es) | Composicion farmaceutica estable | |
EA201500446A1 (ru) | Фармацевтическая композиция для снижения уровня n-оксида триметиламина | |
IN2014CN04119A (es) | ||
IN2012CH05549A (es) | ||
AR081049A1 (es) | Medicamento oftalmico para el tratamiento de la hipermetropia | |
TR201105424A2 (tr) | Çinko etken maddeli bir farmasötik formülasyon. | |
CR20140526A (es) | Dronedarona para uso en la leishmaniosis, formulaciones y asociaciones para uso en la leishmaniosis | |
UY31669A1 (es) | "formulación farmacéutica que comprende oxabispidinas /236" | |
TR200906322A2 (tr) | Çözünürlük ve stabilite özellikleri geliştirilmiş granüller. | |
TR200806302A2 (tr) | Çözünürlük ve stabilite artırıcı farmasötik formülasyon. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |